BioSpace News Archive

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19 th , 2020 to discuss the 2 nd quarter 2020 financial results and business update. The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to join the Teligent, Inc. call. This ca

BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2020. Brady Granier, CEO, and Director of BioCorRx, Inc., stated, “Despite the COVID-19 pandemic, our pivotal GLP preclinical studies of BICX102, a sustained release naltrexone implant for the treatment of opioid and a

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with Attwill Medical Solutions Sterilflow, LP (“AMS”) to establish AMS as a resource for clinical packaging and distribution for the Company’s Phase 3 clinical trial to ev

nc. Magazine revealed this week that Aspen Laser Systems has been selected for its Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in the United States

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today reported financial results for the second quarter ended June 30, 2020 and provided an update on its business.

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due to the results that AAGP® has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing.

PPD, Inc. (Nasdaq:PPD) today announced that two PPD senior leaders have been named to the 2020 PharmaVOICE 100 list of the most inspiring people in the life sciences industry: Karen Kaucic, M.D., chief medical officer of PPD and president of Evidera, and Rhonda Henry, vice president of patient-centered trials.

Vaso Corporation reported its operating results for the three months ended June 30, 2020.

Rafarma Pharmaceuticals, Inc.OTC:(RAFA) is pleased to update its shareholders on the progress of its acquisition by the R. & D. BIOCOGENCY LABORATORIES Group of Companies (“Biocogency”) of Cyprus.

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete Presents New Preclinical Data Showing That ALG.APV-527 has Potential for a Favorable Safety Profile Extends Cash Runway into Q3 2021 Providing Runway Through Our Anticipated Clinical Data